Furthermore, CCL2 levels have been suggested to be a potential marker for disease surveillance following treatment of non-small cell lung cancer with anlotinib, a tyrosine receptor kinase inhibitor, which was found to suppress xenograft angiogenesis through CCL2 inhibition33. This evidence concerns the gene CCL2 and non-small cell lung carcinoma.